Top Markets
#1 Pleasing Gold Pleasing Gold +1,501.62%
#2 Ontology Gas Ontology Gas +182.29%
#3 PulseChain PulseChain +57.88%
#4 Ontology Ontology +40.20%
#5 ConstitutionDAO ConstitutionDAO +36.86%
#6 Osmosis Osmosis +36.34%
#7 BOOK OF MEME BOOK OF MEME +31.61%
#8 Collect on Fanable Collect on Fanable +26.31%
#9 Neiro Neiro +25.71%
#10 Pump.fun Pump.fun +24.19%
Coin of the day
Pleasing Gold Pleasing Gold
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Icosavax, Inc. Icosavax, Inc.

Icosavax, Inc.

ICVX
Kedudukan dalam Saham #25854
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing... Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Harga Saham
$15.31
Disegerakkan terakhir: 2024-02-29
Modal Pasaran
$45.70M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Icosavax, Inc. (ICVX)

Kategori

Healthcare
Pendapatan untuk Icosavax, Inc. (ICVX)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Icosavax, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Icosavax, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US